Also known as: Lexeo Therapeutics
Lexeo Therapeutics is a clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The company also pursues therapies for APOE4-associated Alzheimer’s disease and other genetically defined conditions.
Phase 1 data in 17 adults with Friedreich's ataxia cardiomyopathy showed AAVrh.10hFXN (LX2006) was generally well tolerated and showed signs of biological activity. The gene therapy is being advanced into a larger trial.
Multiple therapeutic approaches targeting the APOE4 gene are advancing, including small molecule drugs, gene therapies, and repurposed medications. The APOE4 variant confers a 60% lifetime Alzheimer's risk and affects brain metabolism, increasing seizure susceptibility. Research shows blood pressure drug terazosin can reduce seizures in APOE4 models by boosting cellular energy production.
The FDA has denied or discouraged at least eight drug applications in the past year, including treatments for rare diseases, raising concerns about regulatory consistency and the future of experimental therapies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06865482 |
Clinical Course Of Disease In Participants With FA-CM |
RECRUITING |
